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Abstract
Background: The brain-derived protein S100B has been shown to be a useful marker of brain
injury of different etiologies. Cognitive dysfunction after cardiac surgery using cardiopulmonary
bypass has been reported to occur in up to 70% of patients. In this study we tried to evaluate S100B
as a marker for cognitive dysfunction after coronary bypass surgery with cardiopulmonary bypass
in a model where the inflow of S100B from shed mediastinal blood was corrected for.
Methods:  56 patients scheduled for coronary artery bypass grafting underwent prospective
neuropsychological testing. The test scores were standardized and an impairment index was
constructed. S100B was sampled at the end of surgery, hourly for the first 6 hours, and then 8, 10,
15, 24 and 48 hours after surgery. None of the patients received autotransfusion.
Results: In simple linear analysis, no significant relation was found between S100B levels and
neuropsychological outcome. In a backwards stepwise regression analysis the three variables,
S100B levels at the end of cardiopulmonary bypass, S100B levels 1 hour later and the age of the
patients were found to explain part of the neuropsychological deterioration (r = 0.49, p < 0.005).
Conclusions: In this study we found that S100B levels 1 hour after surgery seem to be the most
informative. Our attempt to control the increased levels of S100B caused by contamination from
the surgical field did not yield different results. We conclude that the clinical value of S100B as a
predictive measurement of postoperative cognitive dysfunction after cardiac surgery is limited.
Background
Despite the fact that incidence figures between 4–79%
have been reported for cognitive dysfunction after cardiac
surgery [1], diagnostic steps are seldom taken to diagnose
this impairment. The golden standard for detecting cogni-
tive dysfunction is neuropsychological tests, which are
complex and difficult to use as a routine procedure. Lately
the brain derived protein S100B has been proposed as a
simple method for detecting brain dysfunction after car-
diac surgery [2-5]. The protein is a member of the larger
S100 family, where S100B is one isoform, and considered
to be brain specific, and the other is the S100A isoform
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[6]. The S100B chain is uniform in contrast to the S100A
chain which exhibits several subgroups. The dimers of
interest in studies concerning cerebral events are those
containing S100B (S100BB and S100A1B). The physio-
logical roles of S100B are pleiotropic including neuro-
trophic and neuroprotective functions, mediated by
calcium dependent regulation of phosporylation, enzyme
activation and proliferation [6]. On the other hand, high
concentrations of S100B have been shown to be toxic and
induce apoptosis in neuronal cell cultures [7,8]. At least
five experimental studies have indicated a possible role of
S100B in learning and memory function, three of which
reported impaired memory and learning effects in trans-
genic S100B mice and two reported memory deficits after
injection of S100B antiserum [9-13].
Several studies in humans suffering from stroke of differ-
ent ethiologies, have shown a rather strong correlation
between serum levels of S100B and size of lesion(s) as
well as outcome [14-17].
Lately a number of studies have addressed the question
whether S100B can be considered as a marker for cogni-
tive dysfunction after cardiac surgery; however the conclu-
sions presented are disparate. One major reason for this
could be the fact that S100B is present in high concentra-
tions in shed mediastinal blood that is retransfused to the
patient by cardiotomy suction and autotransfusion, thus
obscuring the measured levels of S100B early after sur-
gery. To date, only one study have been published where
this contamination was taken into account [18]. We
recently reported the half life of S100B in serum to be 25
min [19]. With the present study we wanted to use our
knowledge of inflow and elimination to obtain a more
reliable measurement of cerebral release of S100B after
cardiac surgery and correlate it with neuropsychological
outcome.
Methods
Study design
The study group comprised 56 patients who underwent
coronary artery bypass graft (CABG) surgery at the Divi-
sion of Cardiac Surgery, University Hospital MAS, Mal-
moe, Sweden and Department of Cardiothoracic Surgery,
Lund University Hospital, Lund, Sweden. Only patients
planned for elective CABG with cardiopulmonary bypass
(CPB) as their sole procedure were included. The study
protocol was approved by the local ethics committee, and
patients gave a written informed consent before the study
protocol was initiated. Patients with a history of stroke,
transient ischemic attack (TIA), reversible neurological
disorder (RIND), known carotid artery disease or other
brain diseases were excluded. In order to avoid possible
influence of renal disorder on the elimination of S100B,
patients with known renal failure (Creatinin > 160 µmol/
L) were excluded.
The patients were examined for signs of neurological dys-
functions daily during the hospital stay by either experi-
enced cardiac anesthesiologists or by experienced cardiac
surgeons.
Perioperative management
Anesthesia was induced with midazolam 3–5 mg iv (Dor-
micum®, Roche, Basel, Switzerland) or propofol
(Diprivan®, Zeneca Ltd, Cheshire, England) 10 mg/kg. It
was subsequently maintained with fentanyl 10 µg/kg
(Leptanal®, Janssen Pharmaceutica, Beerse, Belgien), a
continuous infusion of propofol 3–6 mg/kg/h or inhala-
tion of isoflurane 0,5–1% (Forene®, Abbott Laboratories).
Nitrous oxide (Aga Industries, Stockholm, Sweden) was
used before CPB but not during or after CPB.
CABG surgery was performed during aortic cross clamping
with the distal anastomosis preceding the proximal anas-
tomosis. A tangential occluder replaced the cross-clamp
during the proximal anastomosis. Antegrade cold S:t Tho-
mas crystalloid cardioplegia was used (Cardioplegi®, Phar-
macia-Upjohn, Uppsala, Sweden) and administered in
the ascending aorta and the anastomosed vein-grafts
intermittently.
Perfusion was performed with a roller pump (Cobe Indus-
tries, Denver, Colorado, USA). The perfusion catheters
and circuit were made of polyvinylchloride in the line and
silicon in the pumphead. The arterial cannulation was
made in the ascending aorta and venous cannulation in
the right atrium by a two-stage venous cannula. All circuits
contained a heparin-coated 40 µm arterial filter (Cobe
Sence, Cobe Industries) and a membrane oxygenator
(Cobe Duo oxygenator, Cobe Industries). The circuit was
primed with approximately 1000 ml of Ringer's lactate
(Pharmacia-Upjohn), 250 ml 15% Mannitol (Pharmacia-
Upjohn) and 75 mmol Addex tromethamine (Pharmacia-
Upjohn). Perfusion flow was non-pulsatile with a flow
rate of 2.4 l/min/m2 at normothermia. The perfusate was
cooled to approximately 32°C. Heparin (400 U/kg body-
weight) was given prior to cannulation and reversed with
equal doses of protamine sulphate at decannulation.
After surgery, the patients patient were transferred to the
ICU for recovery and enrolled in the sampling scheme for
S100B analysis. None of the patients received
autotransfusion.
S100-protein analysis and calculations
Serum for S100B analysis was sampled before surgery, at
the end of CPB, and then 1, 2, 3, 4, 5, 6, 8, 10, 15, 24 and
48 hours after surgery. The S100B levels at these timeBMC Neurology 2004, 4:24 http://www.biomedcentral.com/1471-2377/4/24
Page 3 of 7
(page number not for citation purposes)
points will be referred to as T0, T1, T2....T48. Blood sam-
ples, both arterial and venous samples, were cooled and
centrifuged within 5 hours. All samples were measured by
a monoclonal two-site immunoluminometric assay
(Sangtec 100, AB Sangtec Medical, Bromma, Sweden).
S100B kinetic calculations
Since early levels of S100B are contaminated by S100B
from cardiotomy suction, an attempt was made to exclude
this S100B from the levels measured one and two hours
after surgery. Assuming that all of the measured S100B at
the termination of CPB was a contamination, this non-
cerebral S100B was eliminated with a half-life of 25 min-
utes, as illustrated in figure 1a and 1b. The estimated true
levels cleansed from the contamination 1 and 2 hours
after the end of surgery were thereby calculated by the
formula:
where Ce is the estimated true levels of S100B at time t, Ct
= the measured concentration of S100B at T1 or T2, C0 the
concentration at the end of CPB, t the time after T0 and t1/
2 the half-life of S100B.
We have earlier suggested that the elimination rate could
be used as another measure of cerebral release [5], and the
elimination rates of S100B between the end of CPB (T0)
1a – Measured S100B release pattern in one patient and the calculated residual levels from the S100B from cardiotomy suction  during surgery, a half-life of 25 minutes was used Figure 1
1a – Measured S100B release pattern in one patient and the calculated residual levels from the S100B from cardiotomy suction 
during surgery, a half-life of 25 minutes was used. 1b – Estimated true release, calculated by subtracting the residual levels 
(from 1a) from measured levels. 1c – Measured levels and estimated true release from one patient with high S100B at T0 and 
low estimated true release at T1. This patient also had a good neuropsychological outcome. 1d – Measured levels and esti-
mated true release from one patient with low S100B at T0 and high estimated true release at T1. This patient had a bad neu-
ropsychological outcome.
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and 1 hour later, between T1 and T2, and between T2 and
T3 were calculated accordingly. The differences between
measured S100B levels at T0 and T1, T0 and T2 were also
calculated.
Neuropsychological method
The patients underwent neuropsychological testing by the
same trained neuropsychologist 1–2 days before and 5–7
days after surgery. The tests used were: Mental Control,
Figural Memory, Logical Memory (A/B), Visual Reproduc-
tion, Rey Auditory/Verbal Learning Test (RAVLT), Trail
Making A, Trail Making B, Digit Symbol, Digit Span, Vis-
ual Memory Span, Visual Paired Associates II or Verbal
Paired Associates I and RAVLT, Delayed Retention. The
tests were chosen from the Wechsler Memory Scale-
Revised (WMS-R), the Wechsler Adult Intelligence Scale
(WAIS – R) and the Halsted-Reitan Neuropsychological
Battery [20,21].
Differences for each sub-test were first calculated and then
standardized to z-values. All sub-tests were then aggre-
gated to create an impairment index [4]. The impairment
index was a continuous variable, where a positive value
reflected an improvement in neuropsychological test and
a negative value reflected deterioration. The incidence of
neuropsychological impairment in the study group was
calculated according to the 1 standard deviation criterion
(SD) as defined by Newman and the 20% criterion as
defined by Stump [22-24].
Statistical analysis
All results were analyzed with the Statistica version 5.0 for
PC. Regression analysis was performed with the least
square method with a casewise deletion of missing data.
For the multiple regression a backwards stepwise regres-
sion was performed to determine which variables to
include in the final analysis. The initial variables included
in this analysis were age, gender, perfusion time, years of
education, and S100B levels at all sampling times. A p-
value < 0,05 was considered significant. Unless otherwise
stated numerical values are presented as mean ± 1 stand-
ard deviation.
Results
Patient demographics are presented in table 1. None of
the patients suffered a clinically detectable stroke. The
incidence of neuropsychological impairment was 37,5%
(n = 21, 95% C.I 26,0–50,6%) according to the 1 standard
deviation criterion, and 80,4% (n = 45, 95% C.I. 68,1–
88,6%) according to the 20% criterion.
The appearance of S100B protein followed the same pat-
tern in all patients with high levels at the end of CPB and
a decrease or slight increase the first hour (figure 2).
Thereafter a subsequent decrease was observed during the
rest of the study period, except in one patient in whom the
concentration of S100B increased to 2,0 µg/L 48 hours
after surgery. Mean estimated true release of S100B, calcu-
lated according to equation [1], was lower at T1 and T2
compared to measured S100B levels (1.43 ± 1.37 µg/L vs.
2.11 ± 1.81 µg/L and 1.22 ± 1.10 µg/L vs. 1.32 ± 1.17 µg/
L). Three representative examples of this calculation are
shown in figure 1b, 1c and 1d.
We found a correlation between patient age and S100B
levels measured up to 24 hours after bypass (Table 2). No
significant correlation was found between measured
S100B levels at the sampling times and neuropsychologi-
cal impairment in simple regression analysis (Table 3).
Neither did age, years of education and duration of per-
fusion correlate with neuropsychological impairment
when tested in simple regression analysis (Table 3).
In multiple regression analysis, measured S100B levels at
the end of CPB (T0), one hour later (T1) and age were
Table 1: Demographics for the study group.
Mean St. dev.
Number 56
Sex (M/F) 47/9
Age (years) 60.4 9.0
Education (years) 9.6 3.1
Perfusion time 
(Minutes)
82.8 31.5
X-clamp (minutes) 53.9 23.5
S100B release pattern after cardiac surgery with cardiopul- monary bypass shown as a boxplot Figure 2
S100B release pattern after cardiac surgery with cardiopul-
monary bypass shown as a boxplot.
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found to explain part of the neuropsychological
impairment (r = 0.49, p < 0.005, Table 4). It is worth not-
ing that the correlation was positive at T0 and negative at
T1, implicating a better outcome if S100B was high at T0
and worse if the levels were high at T1. Age had a negative
correlation. Furthermore the combination of age, S100B
at T0 and S100B at either T3 or T6 gave significant corre-
lations in the same manner (r = 0.41, p < 0.05 and r =
0.42, p < 0.05 respectively). The difference between S100B
levels at T0 and T1 was found to correlate positively with
neuropsychological outcome (Table 3). No correlation
was found when the estimated true release of S100B was
tested against neuropsychological outcome, neither did
the elimination rate fall out significantly in simple regres-
sion analysis (Table 3).
Discussion
This study presents some interesting findings that may be
relevant in clinical practice. There is a clear relation
between patient age and release of S100B up to 24 hours
after cardiac surgery. This correlation is strong and not
influenced by the perioperative contamination of S100B
caused by the use of coronary suction [4].
The univariate analysis did not provide a clear answer to
the question whether there is a relationship between neu-
ropsychological outcome and S100B release. However,
from table 3 it is worth noting that the r-values in univar-
iate regression analysis are negative at all sampling points
except at T0 (immediately after bypass). The consistent
finding of a negative correlation 1 hour and onwards after
bypass is intriguing and warrants further exploration.
The multiple regression analysis resulted in a significant
correlation between neuropsychological deterioration
and the three variables: S100B at T0, S100B at T1 and
patient age. The r-value in the multiple regression analysis
was 0.49, which evokes the question why the multiple
regression is stronger than the univariate regression. One
possible explanation could be that by including the S100B
level at the end of CPB we compensate for some part of
Table 2: The relation between S100B levels and patient age 
tested in univariate linear regression analysis.
r-value p-level
S100B at T0 0.19 n. s
S100B at T1 0.30 <0.05
S100B at T2 0.30 <0.05
S100B at T3 0.34 <0.05
S100B at T4 0.37 <0.05
S100B at T5 0.32 <0.05
S100B at T6 0.37 <0.05
S100B at T8 0.38 <0.01
S100B at T10 0.42 <0.005
S100B at T15 0.36 <0.05
S100B at T24 0.46 <0.005
S100B at T48 0.004 n.s
Table 3: The relation between S100B levels, demographic 
variables and neuropsychological impairment index, expressed 
as r-value from linear regression analysis (* = p < 0.05). Mean (± 
SD) S100B levels are also presented. (Est. true release = 
estimated true release when residual levels from contamination 
have been excluded)
Mean ± St.dev. r-value
S100B at T0 3.63 ± 2.84 0.08
S100B at T1 2.11 ± 1.81 -0.16
S100B at T2 1.32 ± 1.17 -0.11
S100B at T3 0.87 ± 0.73 -0.12
S100B at T4 0.60 ± 0.42 -0.06
S100B at T5 0.49 ± 0.38 -0.12
S100B at T6 0.42 ± 0.33 -0.15
S100B at T8 0.38 ± 0.25 -0.12
S100B at T10 0.31 ± 0.21 -0.06
S100B at T15 0.25 ± 0.16 -0.09
S100B at T24 0.21 ± 0.11 -0.10
S100B at T48 0.21 ± 0.27 -0.09
Est. true release at 
T1
1.43 ± 1.37 -0.22
Est. true residual at 
T2
1.22 ± 1.10 -0.12
Elimination rate T0-
T1
0.50 ± 0.46 0.26
Elimination rate T1-
T2
0.48 ± 0.25 -0.05
Elimination rate T2-
T3
0.68 ± 0.32 -0.12
Difference T0-T1 1.53 ± 1.66 0,30*
Difference T0-T2 2.31 ± 2.01 0,18
Age 0.16
Education -0.06
Perfusion time 0.12
Table 4: The results of the backwards stepwise multiple 
regression analysis model to explain the neuropsychological 
impairment index (r = 0.49, p < 0.005).
Variable Partial correlation Beta p-value
S100 at T0 0.45 0.845 <0.005
S100 at T1 -0.47 -0.939 <0.001
Age 0.31 0.307 <0.05
Regression <0.005BMC Neurology 2004, 4:24 http://www.biomedcentral.com/1471-2377/4/24
Page 6 of 7
(page number not for citation purposes)
the contamination in the S100B levels one hour after
surgery.
Age correlated also with outcome. As expected, the older
the patient the higher the risk for neuropsychological
deterioration, which is in accordance to the fact that age is
a risk factor for decline in neuropsychological tests after
surgery [23].
Our results are to some extent in concordance with other
reports in this field. Two groups have reported no relation
between S100B and neuropsychological test results,
[2,18] and two groups have found a relation using a com-
posite S100B end-point [3,4]. Only one of these studies
was designed to exclude the extracerebral inflow of S100B
[18]. These contradicting findings support our notion that
S100B kinetics after cardiac surgery are complicated.
Interestingly, in the multiple regression analysis there was
a positive correlation between S100B levels at T0 and out-
come, a finding that stands in contrast to the hypothesis
that S100B could be used as serum marker for cognitive
dysfunction. This finding is especially interesting since
most of the measure S100B at T0 is contamination. In an
earlier study we found that approximately 80% of meas-
ured S100B at this point is from extracerebral sources in
CABG patients [4]. We offer no explanation for this unex-
pected finding, but it is intriguing and calls for further
investigations.
When interpreting the results of our study, as well as com-
paring them with those of other reports, several issues
need to be addressed. To begin with the origin of S100B
measured after CPB is not exclusively cerebral. From our
previous study as well as from reports by Anderson et al
[25], it is clear that shed blood in the mediastinum con-
tains very high levels of S100B. When this blood is
retransfused either directly by cardiotomy suction or later
in the course by autotransfusion during the postoperative
care, the systemic levels of S100B are affected. The source
of this S100B is non-cerebral, probably from S100B con-
taining tissue such as fat, skin and bone marrow. No
autotransfusion was used in this study, however reabsorb-
tion of S100B from injured fat tissue may contribute to
the measured serum levels of S100B.
Since we previously have been able to determine the half
life of S100B in blood to be 25 min, it was possible to con-
trol for the peri-operative contribution from cardiotomy
suctions by using the equation mentioned to obtain the
estimated true release at T1 and T2. When these values
were entered in simple regression analysis, no correlation
was found to neuropsychological outcome. However, if
multiple regression analysis was used, a positive correla-
tion was found, these results were identical to those
obtained with the measured S100B values, and therefore
we can conclude that the use of the correction procedure
represented by the equation does not contribute to the
evaluation of the results. Moreover, we should be careful
to overinterpret the significance of correlations in a study
of relatively few patients and several end-points, i.e sam-
pling times for S100B. There is always a risk of accepting
a false hypothesis. Preferably, a study of this sort should
contain a large number of patients and only one or few
end-points. However, the aim of this study was to clarify
the complex kinetics of early S100B release and its possi-
ble connection to a neuropsychological decline, not to
determine the perfect use of S100b for detecting neu-
ropsychological outcome after cardiac surgery.
In the mathematical correction model suggested here, we
assume that all S100B measured at T0 is of extrecerebral
origin. This is of course not the case, but we do not know
the relation between cerebral and extracerebral S100B at
this time-point in each individual. By assuming that none
of the S100B measured at T0 is of cerebral origin, we can
be sure that our mathematical model does not include
non-cerebral S100B at T1 and later. However, these levels
might be lower than the true levels of cerebral S100B since
we could have excluded cerebral S100B present at T0. This
could also be an explanation that the multiple regression
analysis showed stronger correlations.
One important issue, which must be considered in this
type of study, is the strength that can be expected in the
correlation between two different measures of brain func-
tion. The functional domains in the brain covered by neu-
ropsychological tests vary depending on the tests used and
are by no means complete in any test battery. By the same
reasoning, the magnitude of a possible cerebral release of
S100B after an injury may vary according to the severity of
the insult as well as the location of the insult, since glia
dense areas express more S100B than others [26].
Conclusions
In conclusion, with the present knowledge, a single S100B
sampled in the postoperative course after cardiac surgery
can not be of use in clinical practice in order to predict
neuropsychological outcome with an acceptable
sensitivity.
However, utilizing a statistic model, an association
between S100B levels the first hours after surgery and neu-
ropsychological outcome was found, where the most
informative time point seems to be 1 hour after the termi-
nation of CPB.
The controversial significance of an increased S100B
immediately after surgery is indeed intriguing and it
inspires further studies of the mechanisms of S100BBMC Neurology 2004, 4:24 http://www.biomedcentral.com/1471-2377/4/24
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release after cardiac surgery as well as other fields of brain
damage.
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